Get started
Work

Circulating Cell-Free DNA in Renal Cell Carcinoma: The New Era of Precision Medicine

Year: 2022
Type: review
Abstract: Tumor biopsy is still the gold standard for diagnosing and prognosis renal cell carcinoma (RCC). However, its invasiveness, costs, and inability to accurately picture tumor heterogeneity represent major limitations to this procedure. Analysis of circulating cell-free DNA (cfDNA) is a non-invasive cost-effective technique that has the potential to ease cancer detection and prognosis. In particular, a growing body of evidence suggests that cfDNA could be a complementary tool to identify and prognosticate RCC while providing contemporary mutational profiling of the tumor. Further, recent research highlighted the role of cfDNA methylation profiling as a novel method for cancer detection and tissue-origin identification. This review synthesizes current knowledge on the diagnostic, prognostic, and predictive applications of cfDNA in RCC, with a specific focus on the potential role of cell-free methylated DNA (cfMeDNA).
Source: Cancers
DOI: 10.3390/cancers14184359
Authors: Edoardo Francini, Giuseppe Nicolò Fanelli, Filippo Pederzoli, Sandor Spisak, Erika Minonne, Massimiliano Raffo, Hubert Pakula, Viktoria Tisza, Cristian Scatena, Antonio Giuseppe Naccarato, Massimo Loda, Pier Vitale Nuzzo
Institutions: University of Florence, University of Pisa, Weill Cornell Medicine, Institute of Molecular Life Sciences, HUN-REN Research Centre for Natural Sciences, University of Turin, Vita-Salute San Raffaele University, IRCCS Ospedale San Raffaele
Language: English
Subfield: Cancer Research
Open Access status: gold
Estimated APC paid: $2,513
OpenAlex ID: W4295106785
FWCI: 0.572
Cites: 90
Cited by: 22
Related to: 10